SHA: 600332

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025

Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) announced its intention to acquire 100% equity of...

Drug

Guangzhou Baiyunshan Pharmaceutical Launches Phase I/II Trial for RET‑Targeted BYS10

Fineline Cube Sep 16, 2025

Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (SHA: 600332) announced that the Center for Drug Evaluation (CDE)...

Company Deals

Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts

Fineline Cube Jun 24, 2022

China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off...

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen